Immunogenicity and in vivo protection of a variant nanoparticle vaccine that confers broad protection against emerging SARS-CoV-2 variants
Johnson, Robert M.
Portnoff, Alyse D.
McGrath, Marisa E.
Haupt, Robert E.
Weston, Stuart M.
Plested, Joyce S.
Greene, Ann M.
Glenn, Greg M.
Frieman, Matthew B.
MetadataShow full item record
AbstractThe severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) continues to spread globally. As SARS-CoV-2 has transmitted from person to person, variant viruses have emerged with elevated transmission rates and higher risk of infection for vaccinees. We present data showing that the Novavax® recombinant prefusionstabilized Spike (rS) protein based on the B.1.351 sequence (rSB.1.351) was highly immunogenic in mice and produced neutralizing antibodies against SARS-CoV-2/WA1, B.1.1.7, and B.1.351. Mice vaccinated with the Novavax® prototype vaccine NVX-CoV2373 (rSWU1) or rS-B.1.351 alone, in combination, or as a heterologous prime boost, were protected when challenged with live SARS-CoV-2/B.1.1.7 or SARS-CoV-2/B.1.351. Virus titer was reduced to undetectable levels in the lungs post-challenge in all vaccinated mice, and Th1-skewed cellular responses were observed. A strong anamnestic response was demonstrated in baboons boosted with rS-B.1.351 approximately one year after immunization with NVX-CoV2373 (rS-WU1). An rS-B.1.351 vaccine alone or in combination with prototype rS-WU1 induced protective antibody- and cell-mediated responses that were protective against challenge with SARS-CoV-2 variant viruses.
DescriptionPoster presented at the American Society for Virology Annual Meeting, July 18, 2022
Rights/TermsAttribution-NonCommercial-NoDerivatives 4.0 International
Identifier to cite or link to this itemhttp://hdl.handle.net/10713/19373
The following license files are associated with this item:
- Creative Commons
Except where otherwise noted, this item's license is described as Attribution-NonCommercial-NoDerivatives 4.0 International